You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Omeros granted CEO Gregory A. Demopulos, M.D., an option for up to 500,000 shares at $17.88 per share on October 28, 2026, vesting across four tranches tied to $25.00, $30.00, $35.00 and $40.00 price hurdles and continued service, expiring October 28, 2031.
Useful current figures from the complete screener profile.
TL;DR. YARTEMLEA gross revenue increased 190% sequentially to $32.2 million in the second quarter, producing $4.1 million of company-wide operating cash flow, adjusted net income, and a slight operating profit. The company also repurchased $30.5 million of 2029 Notes, but withheld revenue guidance, expects higher third-quarter operating expenses, and faces a negative CHMP opinion under re-examination.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Net cash provided by operations | $4.1M | Q2 2026 | — |
| Non-GAAP adjusted net income non-GAAP | $1.8M | Q2 2026 | — |
| Outstanding principal amount of 2029 Notes remaining | $40.3M | Q2 2026 | — |
| Shares issuable upon conversion of 2029 Notes (remaining) | 6.5M | Q2 2026 | — |
| Shares of common stock repurchased | 0.8M | Six months ended June 30, 2026 | — |
| YARTEMLEA gross revenues | $32.2M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OMER
this stock
Omeros Corp
|
$1.27B | +1.8% | -53.9% | — | 17.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Omeros granted CEO Gregory A. Demopulos, M.D., an option for up to 500,000 shares at $17.88 per share on October 28, 2026, vesting across four tranches tied to $25.00, $30.00, $35.00 and $40.00 price hurdles and continued service, expiring October 28, 2031.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OMER | +3.4% | +8.0% | +50.1% | -5.2% | +1.8% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +0.8% | +9.1% | +49.6% | -5.0% | -8.8% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
